105.14
price down icon2.30%   -2.48
after-market After Hours: 105.14
loading
Ligand Pharmaceuticals Inc stock is traded at $105.14, with a volume of 153.42K. It is down -2.30% in the last 24 hours and down -13.98% over the past month.
See More
Previous Close:
$107.62
Open:
$105.55
24h Volume:
153.42K
Relative Volume:
1.47
Market Cap:
$2.11B
Revenue:
$152.42M
Net Income/Loss:
$45.24M
P/E Ratio:
41.89
EPS:
2.51
Net Cash Flow:
$6.97M
1W Performance:
-5.85%
1M Performance:
-13.98%
6M Performance:
+5.05%
1Y Performance:
+43.83%
1-Day Range:
Value
$103.06
$106.37
1-Week Range:
Value
$103.06
$112.53
52-Week Range:
Value
$67.72
$129.90

Ligand Pharmaceuticals Inc Stock (LGND) Company Profile

Name
Name
Ligand Pharmaceuticals Inc
Name
Phone
858-550-7500
Name
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Name
Employee
0
Name
Twitter
@Ligand_LGND
Name
Next Earnings Date
2025-02-18
Name
Latest SEC Filings
Name
LGND's Discussions on Twitter

Compare LGND with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
LGND
Ligand Pharmaceuticals Inc
105.14 2.11B 152.42M 45.24M 6.97M 2.51
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-03-24 Initiated Oppenheimer Outperform
Jul-30-24 Initiated RBC Capital Mkts Outperform
Apr-14-21 Resumed Stephens Overweight
Feb-04-21 Reiterated H.C. Wainwright Buy
Oct-06-20 Initiated Barclays Overweight
Mar-24-20 Downgrade Argus Buy → Hold
Mar-10-20 Initiated Guggenheim Neutral
Feb-06-20 Initiated The Benchmark Company Buy
Sep-19-19 Upgrade Barclays Equal Weight → Overweight
Jun-11-19 Initiated Barclays Equal Weight
May-03-19 Reiterated H.C. Wainwright Buy
Mar-06-19 Reiterated H.C. Wainwright Buy
Oct-29-18 Upgrade ROTH Capital Neutral → Buy
Oct-02-18 Reiterated H.C. Wainwright Buy
Sep-11-18 Reiterated Argus Buy
Aug-17-18 Initiated Goldman Neutral
Aug-08-18 Downgrade ROTH Capital Buy → Neutral
Jun-21-18 Initiated Argus Buy
Dec-27-17 Reiterated H.C. Wainwright Buy
Sep-05-17 Resumed H.C. Wainwright Buy
Oct-05-16 Reiterated H.C. Wainwright Buy
Aug-05-16 Downgrade Deutsche Bank Hold → Sell
Mar-11-16 Initiated Sidoti Buy
Mar-03-16 Initiated H.C. Wainwright Buy
View All

Ligand Pharmaceuticals Inc Stock (LGND) Latest News

pulisher
07:58 AM

PALVELLA THERAPEUTICS, INC. SEC 10-K Report - TradingView

07:58 AM
pulisher
03:38 AM

Teacher Retirement System of Texas Boosts Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

03:38 AM
pulisher
Mar 30, 2025

HighTower Advisors LLC Boosts Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Raymond James Financial Inc. Makes New $2.34 Million Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 30, 2025
pulisher
Mar 26, 2025

Swiss National Bank Has $3.86 Million Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 26, 2025
pulisher
Mar 20, 2025

Charles Schwab Investment Management Inc. Increases Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Ligand’s Second Quarter Financial Results to be Reported August 3rd - Business Wire

Mar 19, 2025
pulisher
Mar 19, 2025

Victory Capital Management Inc. Buys 200 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

Ligand Pharmaceuticals (NASDAQ:LGND) Rating Increased to Hold at StockNews.com - Defense World

Mar 18, 2025
pulisher
Mar 18, 2025

US Bancorp DE Acquires 98 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 18, 2025
pulisher
Mar 16, 2025

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Purchased by Atria Investments Inc - Defense World

Mar 16, 2025
pulisher
Mar 13, 2025

Bank of New York Mellon Corp Sells 4,847 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Smartleaf Asset Management LLC Buys 221 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Insider Sell Alert: Octavio Espinoza Sells Shares of Ligand Phar - GuruFocus

Mar 12, 2025
pulisher
Mar 11, 2025

Mutual of America Capital Management LLC Has $307,000 Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 11, 2025
pulisher
Mar 07, 2025

CFO’s Major Stock Sale Shakes Up Ligand Pharma - TipRanks

Mar 07, 2025
pulisher
Mar 06, 2025

Ligand Pharmaceuticals CFO Espinoza sells $575,148 in stock By Investing.com - Investing.com Canada

Mar 06, 2025
pulisher
Mar 06, 2025

Ligand Pharmaceuticals CFO Espinoza sells $575,148 in stock - Investing.com

Mar 06, 2025
pulisher
Mar 06, 2025

Truist Financial Corp Lowers Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

Amalgamated Bank Has $592,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com

Mar 04, 2025
pulisher
Mar 03, 2025

LGND: First Steps into Cell & Gene Therapy - Research Tree

Mar 03, 2025
pulisher
Mar 03, 2025

Ligand CEO and CFO Heading to Miami: Key Investor Access Points for LGND Shareholders - StockTitan

Mar 03, 2025
pulisher
Mar 03, 2025

Ligand to Participate in March Investor Conferences - Yahoo Finance

Mar 03, 2025
pulisher
Mar 02, 2025

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Recommendation of “Buy” by Brokerages - Defense World

Mar 02, 2025
pulisher
Mar 01, 2025

Principal Financial Group Inc. Purchases 6,382 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 01, 2025
pulisher
Feb 28, 2025

Ligand Pharmaceuticals’ Earnings Call Highlights Strong Growth - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Ligand Pharmaceuticals (NASDAQ:LGND) Trading Up 7.3%Should You Buy? - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Ligand Pharmaceuticals (NASDAQ:LGND) Releases Quarterly Earnings Results - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $142 From $151, Maintains Outperform Rating - Marketscreener.com

Feb 28, 2025
pulisher
Feb 28, 2025

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 28, 2025
pulisher
Feb 28, 2025

RBC Raises Price Target on Ligand Pharmaceuticals to $155 From $143, Keeps Outperform Rating - Marketscreener.com

Feb 28, 2025
pulisher
Feb 28, 2025

Ligand Pharmaceuticals Inc (LGND) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance

Feb 28, 2025
pulisher
Feb 27, 2025

Ligand Pharmaceuticals Reports Strong 2024 Financial Growth - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

New York State Common Retirement Fund Boosts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Ligand Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Ligand: Q4 Earnings Snapshot - mySA

Feb 27, 2025
pulisher
Feb 27, 2025

Ligand Pharmaceuticals' Q4 Core Adjusted Net Income, Total Revenue Rise; 2025 Guidance Set - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Ligand Pharmaceuticals Incorporated Reaffirms the Earnings Guidance for the Year 2025 - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Ligand Pharma Slips To Loss In Q4; Confirms FY25 OutlookUpdate - Nasdaq

Feb 27, 2025
pulisher
Feb 27, 2025

LIGAND PHARMACEUTICAL Earnings Results: $LGND Reports Quarterly Earnings - Nasdaq

Feb 27, 2025
pulisher
Feb 27, 2025

Ligand Pharmaceuticals Q4 24 Earnings Conference Call At 8:30 AM ET - Nasdaq

Feb 27, 2025
pulisher
Feb 27, 2025

Ligand: Q4 Earnings Snapshot -February 27, 2025 at 07:24 am EST - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Earnings Flash (LGND) Ligand Pharmaceuticals, Posts Q4 Revenue $42.8M, vs. FactSet Est of $39.0M - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Ligand Pharmaceuticals Inc Q4 Earnings Summary - Nasdaq

Feb 27, 2025
pulisher
Feb 27, 2025

Ligand Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stake Reduced by Rhumbline Advisers - Defense World

Feb 27, 2025
pulisher
Feb 27, 2025

Investor Network: Ligand Pharmaceuticals Incorporated to Host Earnings Call - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 26, 2025

Ligand Pharmaceuticals Inc (LGND) Q4 2024: Everything You Need T - GuruFocus.com

Feb 26, 2025

Ligand Pharmaceuticals Inc Stock (LGND) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Cap:     |  Volume (24h):